Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780746 | 1.00 | DUT (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL21089723 | 1.00 | DUT (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL25399227 | 1.00 | DUT (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL18858899 | 0.93 | DUT (0.53) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL6760952 | 0.92 | DUT (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL24782135 | 0.92 | DUT (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL26373405 | 0.92 | DUT (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL24781265 | 0.92 | DUT (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL10391187 | 0.92 | DUT (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL26373418 | 0.92 | DUT (0.56) | DUTP2RY2P2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | TRILINK BIOTECHNOLOGIES, LLC | 2025-06-26 | — | — | US | disclosed |
| EP-4499824-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023183569-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-6822090-B2 | GENERATION OF PREFERENTIAL URIDINE DERIVATIVE; OBTAIN REACTION MIXTURE, EXPOSE TO TERTIARY AMINE, DEHYDRATING REACTANT AND AMMONIA, RECOVER CYTIDINE DERIVATIVE | MITSUI CHEMICALS, INC. (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20030032797-A1 | Process for the preparation of cytidine derivatives | MITSUI CHEMICALS, INC. (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032797-A1 | Process for the preparation of cytidine derivatives | CDA, DCTD, APOBEC3A | DUT 15/4885P2RY2 3374/4885P2RY6 2224/4885 |
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | RNGTT, POLRMT, POLN | DUT 8/4885P2RY2 3188/4885P2RY6 2972/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | DUT 17/4885P2RY2 101/4885P2RY6 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.